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As in other countries, type 2 diabetes is major health concern in Korea. A dramatic increase in the prevalence of type 2 diabetes 
and its chronic complications has led to an increase in health costs and economic burdens. Early detection of high risk individu-
als, hidden diabetic patients, and improvement in the quality of care for the disease are the first steps to mitigate the increase in 
prevalence. The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the ‘3rd Clini-
cal Practice Guidelines’ at the end of 2010. In the guidelines, the committee recommended active screening of high risk individu-
als for early detection and added the hemoglobin A1c level to the diagnostic criteria for type 2 diabetes based on clinical studies 
performed in Korea. Furthermore, the committee members emphasized that integrating patient education and self-management 
is an essential part of care. The drug treatment algorithm based on the degree of hyperglycemia and patient characteristics were 
also updated.
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INTRODUCTION 
The prevalence of type 2 diabetes mellitus in Korea is estimat-
ed to be 7.3% (in those over 20 years of age), according to a re-
port by the Korea National Health and Nutrition Examination 
Survey (KNHNS III, 2005), an approximately five-fold increase 
from the value 30 years ago [1-3]. The number of patients with 
type 2 diabetes is expected to increase dramatically from about 
3.5 million in 2010 (7.08% of the total population) to about 5.5 
million (10.85%) by 2030 [3,4].
  The obese and overweight population is also increasing 
steadily in Korea; in addition, Korea is becoming one of the 
aged societies in the world. This increase in societal age has 
contributed to the dramatic increase in type 2 diabetic patients. 
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Furthermore, diabetes mellitus was the fifth leading cause of 
death in Korea in 2008 [3]. Therefore, the early detection and 
prevention of type 2 diabetes are major health concerns for 
Korean people and the government. The diagnosis and appro-
priate treatment of type 2 diabetes mellitus are very important 
issues in establishing and implementing high-priority health 
policies in Korea.
SCREENING OF TYPE 2 DIABETES MELLITUS
Recently, several hospital-based or community-based cross-
sectional and cohort studies undertaken in Korea have been 
published. In 2007, the Committee of the Korean Diabetes As-
sociation (KDA) on the Diagnosis and Classification of Diabe-
tes Mellitus analyzed four of these community-based epide-
miological studies performed after 1990, which included 6,234 
subjects, to demonstrate the diagnostic equivalence of fasting 
plasma glucose (FPG) value to a 2-hour plasma glucose (PG) 
value range of 140 and 200 mg/dL. From a receiver operating 
characteristic (ROC) analysis, an FPG cutoff of 110 mg/dL 
corresponded to a 2-hour PG value of 200 mg/dL (sensitivity 
76.4%, specificity 92.2%) [5]. The optimal cutoff point for FPG 
for the diagnosis of impaired glucose tolerance (IGT) in Kore-
an people was 97 mg/dL (sensitivity 57.5%, specificity 71.0%).
Another study that compared the FPG criterion for diagnostic 
screening of diabetes with the 2-hour PG criterion in 1,731 
middle-aged Korean adults showed that the level of agreement 
between the two diagnostic criteria was low (0.268). An ROC 
analysis determined that an FPG of 100 mg/dL yielded opti-
mal sensitivity and specificity and corresponded to a 2-hour 
PG result of 200 mg/dL [6]. If these lower cutoff values are ap-
plied to the diagnosis of diabetes, the prevalence of diabetes is 
more than two-fold higher than when the 2-hour PG level of 
200 mg/dL is used.
  This large discrepancy between the FPG and 2-hour PG cri-
teria in the diagnosis of diabetes and IGT in Koreans is cause 
for hesitation before changing the diagnostic criteria for dia-
betes. We also suggest that the FPG level required for a diag-
nosis of type 2 diabetes mellitus is lower in the Korean and 
Asian populations than in Western populations [5]. For this 
reason, Oh et al. [7] analyzed the IFG population according to 
fasting glucose level, as follows: stage 1 IFG (100 to 109 mg/dL) 
and stage 2 IFG (110 to 125 mg/dL). For subjects in the stage 2 
group, poorer metabolic profiles were detected in terms of to-
tal cholesterol, triglyceride, and high blood pressure. Moreover, 
a greater proportion of people in the stage 2 group were diag-
nosed with diabetes based on the oral glucose tolerance test 
(OGTT). From these results, we suggest that Korean individu-
als with stage 2 IFG should be treated or screened in a differ-
ent manner from those with stage 1 IFG. To avoid missing 
further cases of diabetes, the OGTT should be actively recom-
mended for all individuals with stage 2 IFG. However, in pa-
tients with stage 1 IFG, additional risk factors for diabetes 
should be assessed and an annual glucose test be performed 
(Table 1).
DIAGNOSIS OF TYPE 2 DIABETES MELLITUS
The diagnostic criteria for type 2 diabetes are based on the re-
sults of either the fasting or 2-hour 75 g OGTT, according to 
the observed association between glucose level and the pres-
ence of retinopathy. Until now, there have been no cross-sec-
tional epidemiological studies of Koreans to demonstrate an 
association between PG level and the development of diabetic 
Table 1.  Screening of type 2 diabetes
1. FPG, 75 g OGTT, or HbA1c can be used as screening tests
2.   Annual screening should begin at age 40 years or adults >30 
years who have risk factors 
3.   If FPG or HbA1c are as follows, an additional test should be 
considered 
    Stage 1:   If FPG is in the range of 100 to 109 mg/dL or HbA1c is 
5.7% to 6.0%, annual FPG and HbA1c should be re-
peated annually
    Stage 2:   If FPG is in the range of 110 to 125 mg/dL or HbA1c is 
6.1% to 6.4%, oral GTT should be performed 
OGTT, oral glucose tolerance test; FPG, fasting plasma glucose.
Table 2.  Diagnostic criteria for type 2 diabetes in Korea
A diagnosis of diabetes can be made from any one of the follow-
ing four criteria:
1.   FPG ≥126 mg/dL
2.   2-hour PG ≥200 mg/dL during the oral glucose tolerance 
test
a
3.   Classic symptoms of hyperglycemia or hyperglycemic crisis, 
a random
b PG level ≥200 mg/dL
4.   HbA1c ≥6.5%
Normal activity should be maintained for at least three days before 
sampling. In the absence of unequivocal hyperglycemia, blood sam-
pling should be repeated.
FPG, fasting plasma glucose. “Fasting” means no caloric intake for at 
least 8 hours; PG, plasma glucose.
aGlucose load containing the equivalent of 75 g of anhydrous glucose 
dissolved in water, 
b“Random” is defined as without regard to the time 
since the last meal.433
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retinopathy. The KDA has adopted the diagnostic criteria for 
type 2 diabetes of the American Diabetes Association (ADA) 
(Table 2). Moreover, the variable association between FPG and 
2-hour PG level between populations must be attributed to 
different genetic or environmental backgrounds across differ-
ent ethnic groups. Therefore, more large epidemiological stud-
ies are required to confirm the suitable cutoff values for the 
Korean population.
Oral glucose tolerance test (OGTT) 
The OGTT has low repeatability, requires more time and blood 
samples, and is more expensive than the FPG test. It has not 
been used to screen for type 2 diabetes mellitus and is not rec-
ommended for the diagnosis of type 2 diabetes in routine clin-
ical practice in Korea. However, although FPG is a simple and 
convenient method, a considerable number of type 2 diabetic 
patients cannot be diagnosed based on FPG results alone, as 
discussed above. Several previous studies have shown that the 
FPG criterion is less sensitive for the detection of diabetes in 
elderly Korean people than the OGTT-based criterion [8-10]. 
Therefore, the OGTT remains a valuable test in the diagnosis 
of diabetes and the classification of IGT, especially in elderly 
Koreans. Moreover, OGTT should particularly be considered 
if the subject has a history of impaired fasting glucose, is a high-
risk individual, is pregnant, or to exclude an IGT state.
Hemoglobin A1c (HbA1c)
HbA1c is the gold standard index for follow-up of glycemic 
control. In addition to its role in monitoring and targeting gly-
cemic control, HbA1c has received attention as a diagnostic 
criterion for type 2 diabetes since the ADA included a HbA1c 
value threshold ≥6.5% as a factor with which to diagnose dia-
betes [11]. If we are to consider HbA1c level as a diagnostic 
criterion, priority must be given to standardization of the as-
say method.
  A second consensus meeting on the worldwide standard-
ization of the HbA1c measurement, which included the ADA, 
the European Association for the Study of Diabetes, the Inter-
national Diabetes Federation, the International Federation of 
Clinical Chemistry and Laboratory Medicine (IFCC), and the 
International Society for Pediatric and Adolescent Diabetes, 
stated that the IFCC reference system for HbA1c represents 
the only valid method to standardize the measurement [12]. 
The ADA recommends that HbA1c should be measured ac-
cording to the method certified by the National Glycohemo-
globin Standardization Program and standardized or traceable 
to the Diabetes Control and Complication Trial reference as-
say [11]. Because the HbA1c assay was not standardized 
throughout the country, HbA1c was not recommended as a 
diagnostic criterion for diabetes mellitus in Korea until 2007. 
However, HbA1c standardization has been widely performed 
since 2007 by the Korean Association of Quality Assurance for 
Clinical Laboratory, the Metabolic Disorders Subcommittee, 
the Korean Society of Laboratory Medicine, and the KDA, in-
cluding a nation-wide survey for the current status of the 
HbA1c test [13]. Most commercial laboratories in Korea are 
certified by Designated Comparison Methods, and accuracy-
based proficiency tests are underway. Based on this back-
ground, we included HbA1c as a diagnostic criterion and re-
newed our clinical practice guidelines in 2011. 
  Several studies have been performed in Korea to determine 
the cutoff point for HbA1c required to predict an abnormal 
glucose tolerance status in non-diabetic Korean subjects. Bae 
et al. [14] analyzed 1,482 subjects without diabetes and report-
ed a cutoff point of 5.95% HbA1c to predict diabetes, with a 
sensitivity of 60.8% and specificity of 85.6%. One study that 
included 392 subjects with risk factors for diabetes showed 
that the current guideline of FPG ≥126 mg/dL for diabetes 
screening detected only 55.7% of diabetic subjects. The opti-
mal cutoff points for HbA1c and FPG for the diagnosis of dia-
betes were 6.1% (sensitivity 81.8%, specificity 84.9%) and 110 
mg/dL (sensitivity 85.2%, specificity 88.5%), respectively [15]. 
Ku et al. [16] reported a cutoff point for HbA1c derived from 
the data collected from 19,178 subjects without diabetes. When 
the FPG criterion was used, the cutoff value was 5.9% (sensi-
tivity 84.6%, specificity 85.9%), and when the 2-hour glucose 
level after OGTT was used, the cutoff value was 6.1% (sensi-
tivity 86.5%, specificity 85.8%).
  Based on these clinical results, we suggest that the HbA1c 
cutoff level should be lower than the ADA criterion. However, 
larger epidemiological studies are required to confirm the 
suitable cutoff values for the Korean population.
TARGET OF GLYCEMIC CONTROL
Large prospective, randomized controlled clinical trials such 
as the Kumamoto study [17] and the UK Prospective Diabetes 
Study (UKPDS) [18,19] have showed that early intensive gly-
cemic control in type 2 diabetic patients significantly reduced 
microvascular and macrovascular diabetic complications. Based 434
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on these results, most of the clinical practice guidelines for 
glycemic control target of type 2 diabetes since early the 2000s 
have recommend the achievement of near-normoglycemia to 
prevent diabetic vascular complications. However, three re-
cently published large RCT studies (ACCORD, ADVANCE, 
VADT) have demonstrated no significant benefits in cardio-
vascular outcome with intensive glycemic control in type 2 di-
abetes [20]. From these findings, we agreed not to overlook 
the potential risks of very strict glycemic control in specific 
situations, such as old age with long diabetic duration, com-
bined severe complications, recurrent severe hypoglycemic 
episodes, or limited life expectancy. However, it should be kept 
in mind that many meta-analysis consistently provide evi-
dence for the clinical benefits of achieving and maintaining 
intensive glycemic control to prevent diabetic complications. 
Therefore, a glycemic goal of HbA1c ≤6.5% should be attained, 
especially in the recently diagnosed, young type 2 diabetic pa-
tients without severe complications or hypoglycemia through 
lifestyle modification and glucose-lowering agents, including 
insulin (Table 3, Fig. 1). 
Table 3.  Recommendation of glycemic target in patients with 
type 2 diabetes
1.   FPG and HbA1c can be used as markers of glycemic status 
2.   Achievement and maintenance of intensive glycemic control 
should be used to prevent diabetic microvascular and macro-
vascular complications
3.   Glycemic target should be individualized according to specific 
clinical situation
4.   HbA1c goal can be targeted ≤6.5% in recently diagnosed, 
young-aged patients without severe complications or hypogly-
cemia 
FPG, fasting plasma glucose.
Fig. 1.  Algorithm for the medical management of type 2 diabetes. OHA, oral hypoglycemic agent; CHF, congestive heart failure.
Lifestyle Modification
If not at target within 2-6 months
Add another OHA Add insulin
Triple therapy Multiple-component insulin regimen±OHA
A1C 8.0-10.0% A1C<8.0% A1C>10.0%
OHA monotherapy Insulin±OHA OHA Combination therarpy  
Insulin
Action Mechanism A1C reduction 
(monotherapy)
Side effect Caution
Sulfonylurea (gliclazide glimepiri-
de, glipizide, glibenclamide)
increase insulin secretion 1.0-2.0% Hypoglycemia, weight gain LFT>3-fold Cr>2.0 
mg/dL
Biguanide (Metformin) Decrease hepatic glucose output, 
Improve peripheral insulin sensi-
tivity
1.0-2.0% No hypoglycemia or weight 
gain, GI side effects
eGFR< 30 mL/min 
Old age, dehydration
Alpha-glucosidase inhibitor (acar-
bose, voglibose)
Slowing digestion of carbohydrates 
in small intestine
0.5-0.8% No hypoglycemia or weight 
gain, GI side effects
Cr>1.2 mg/dL Bowel 
disease
Thiazolidinedione (Pioglitazone) Increase the sensitivity of muscle, 
fat, liver to insulin
0.5-1.4% Fluid retention, CHF, 
weight gain, bone fracture
CHF
Meglitinde (repaglinide, nateg-
linide, mitiglinide)
Increase insulin secretion 0.5-1.5% Hypoglycemia, weight gain Hepatic dysfunction
DPPIV inhibitor (sitagliptin, 
vildagliptin)
Enhance GLP-1 & GIP effects, Glu-
cose-mediated insulin secretion, 
suppress glucagon secretion
0.5-0.8% No hypoglycemia or weight 
gain
Renal dysfunction, 
Long-term safety 
not established
GLP-1 receptor agonist (exena-
tide)
Potentiate glucose-stimulated insu-
lin secretion, slow gastric empty-
ing, suppress glucagon secretion
0.5-1.0% No hypoglycemia or weight 
gain, GI side effects
Long-term safety not 
established435
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COMPREHENSIVE MANAGEMENT OF 
METABOLIC RISK FACTORS BEYOND 
GLYCEMIC CONTROL
In addition to glycemic control within the target range, the 
comprehensive management of metabolic risk factors is also 
clinically important. After diagnosis of type 2 diabetes, life-
style modification, as well as medical treatment, should be 
emphasized to prevent cardiovascular events. Lifestyle modifi-
cation could be accomplished by diabetes self-management 
education, including knowledge, self-care behavior, self moni-
toring of blood glucose, medical nutrition therapy, exercise, 
and hypoglycemia. Blood pressure and dyslipidemia should be 
normalized by lifestyle modification and anti-hypertensive or 
lipid-lowering agents. Regular screening for diabetic micro-
vascular or macrovascular complications should be performed 
(Table 4).
CONCLUSION
The dramatic increase in the prevalence of type 2 diabetes and 
its accompanying acute or chronic complications are major 
health concerns in Korea. Screening of high risk individuals, 
early detection, and proper management of type 2 diabetes are 
urgently needed. Although more evidence and clinical trials 
should be undertaken, appropriate clinical practice guidelines 
characterized in Korean people with type 2 diabetes have been 
developed and updated to provide better glycemic control and 
favorable clinical outcomes.
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